Marker Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2020-12-31

Reporting Person: Wasserman Frederick Gerald (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-19	Common Stock	A	17022	$0.00	Acquired	42565	Direct

Footnotes

F1: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the
Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately
preceding the date of the Company's 2019 annual meeting.